Clinical trials: Stage I Multiple Myeloma
Cancer
Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma
RATIONALE: Sodium stibogluconate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Interferon may interfere with the growth of cancer cells.
- Trial name
- NCT00311558
- Testing
- recombinant interferon alfa-2b, sodium stibogluconate, SSG & interferon
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- The Cleveland Clinic
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003406
- Testing
- carboplatin, docetaxel, ifosfamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Cancer Treatment Centers of America
Multiple Myeloma
Stage I Multiple Myeloma Treatment
Assessment of survival without progression of stage I MM in two groups: arm A: simple survey and arm B: administration of Zoledronate.
- Trial name
- IFM-01-04 (NCT00733538)
- Testing
- zometa
- Where
- France
- Volunteers
- 89 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Cancer
Acupuncture in Treating Mucositis-Related Pain Caused by Chemotherapy in Patients Undergoing Stem Cell Transplantation
RATIONALE: Acupuncture may be effective in relieving mucositis-related pain caused by chemotherapy in patients undergoing stem cell transplantation.
- Trial name
- NCT00060021
- Testing
- acupuncture therapy, management of therapy complications, pain therapy
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Relapsed Refractory Multiple Myeloma (RRMM)
Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
This is a phase 1 study to find the recommended dose and schedule of mezigdomide and talquetamab in relapsed and refractory multiple myeloma (RRMM), and to test the effects of the drugs on cancer.
- Trial name
- MAGENTA (NCT07032714)
- Testing
- Talquetamab, Mezigdomide, Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Massachusetts General Hospital
Multiple Myeloma (MM)
A Study of WVT078 in Patients With Multiple Myeloma (MM)
The design of a phase I, open-label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent WVT078 alone and in combination with WHG626 in patients relapses and/or refractory Multiple…
- Trial name
- NCT04123418
- Testing
- WVT078, WHG626
- Where
- 12 sites in United States, Australia and 6 more
- Volunteers
- 56 people
- Sponsor
- Novartis Pharmaceuticals
Partial Response of Multiple Myeloma or Plasma Cell Leukemia, Plasma Cell Myeloma
SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
This phase I trial studies the safety of SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant together with sargramostim in treating patients with newly diagnosed multiple myeloma who are receiving lenalidomide…
- Trial name
- NCT02334865
- Testing
- Incomplete Freund's Adjuvant, Laboratory Biomarker Analysis, Lenalidomide
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Multiple Myeloma
Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma
This is a single arm study to evaluate the efficacy and safety of BCMA-targeted CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.
- Trial name
- NCT06705725
- Testing
- CBG002 CAR-T Cell Suspension
- Volunteers
- 38 people
- Sponsor
- Carbiogene Therapeutics Co. Ltd.
Cancer
Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells.
- Trial name
- NCT00003538
- Testing
- graft versus host disease prophylaxis/therapy, allogeneic bone marrow transplantation
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Multiple Myeloma and Plasma Cell Neoplasm
Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00742404
- Testing
- bortezomib, dexamethasone, pegylated liposomal doxorubicin hydrochloride
- Where
- 12 sites in United States
- Volunteers
- 35 people
- Sponsor
- Oncotherapeutics
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00004904
- Testing
- anti-thymocyte globulin, filgrastim, cladribine
- Where
- United States
- Sponsor
- Northwestern University
Mucositis, Multiple Myeloma and Plasma Cell Neoplasm
Studying Common Genetic Mutations Related to Mucositis in Patients With Multiple Myeloma Receiving High-Dose Melphalan
RATIONALE: Studying blood or mouthwash samples in the laboratory from patients receiving melphalan for cancer may help doctors learn more about changes that occur in DNA, identify biomarkers related to cancer, and help predict…
- Trial name
- NCT00602147
- Testing
- laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 95 people
- Sponsor
- Vanderbilt-Ingram Cancer Center